Acetylcholine is a neurotransmitter that has a major role in the function of the insulin-secreting pancreatic beta cell 1, 2 . Parasympathetic innervation of the endocrine pancreas, the islets of Langerhans, has been shown to provide cholinergic input to the beta cell in several species 1, 3, 4 , but the role of autonomic innervation in human beta cell function is at present unclear. Here we show that, in contrast to the case in mouse islets, cholinergic innervation of human islets is sparse. Instead, we find that the alpha cells of human islets provide paracrine cholinergic input to surrounding endocrine cells. Human alpha cells express the vesicular acetylcholine transporter and release acetylcholine when stimulated with kainate or a lowering in glucose concentration. Acetylcholine secretion by alpha cells in turn sensitizes the beta cell response to increases in glucose concentration. Our results demonstrate that in human islets acetylcholine is a paracrine signal that primes the beta cell to respond optimally to subsequent increases in glucose concentration. Cholinergic signaling within islets represents a potential therapeutic target in diabetes 5 , highlighting the relevance of this advance to future drug development.
Acetylcholine is crucial for pancreatic beta cell function. It stimulates insulin secretion by increasing the cytoplasmic free Ca 2+ concentration, [Ca 2+ ] i , via inositol phosphate production and enhancing the effects of Ca 2+ on exocytosis via protein kinase C in beta cells 1 ( Supplementary Fig. 1 ). Muscarinic receptors found in pancreatic beta cells are essential for maintaining proper insulin secretion and glucose homeostasis in mice 2 . Cholinergic agonists have been reported to restore defective glucose-stimulated insulin secretion 6, 7 . In humans, variations in the gene that encodes the muscarinic receptor M3 are associated with increased risk for early-onset type 2 diabetes 8 . It is generally believed that acetylcholine is released during feeding from parasympathetic nerve endings in pancreatic islets 1, 3 . The consensus is that the endocrine pancreas is richly innervated by the autonomic nervous system 1, 3, 4, 9 , with studies based on the cholinesterase technique revealing dense parasympathetic innervation in cat, rat, rabbit and human islets [10] [11] [12] [13] . Human pancreatic islets, however, have not been examined for the presence of prototypical cholinergic markers such as vesicular acetylcholine transporter (vAChT) or choline acetyltransferase (ChAT).
Cells and nerve fibers capable of vesicular release of acetylcholine express vAChT 14 . We performed immunohistochemistry on mouse and human pancreatic sections and found that mouse islets were densely innervated by vAChT-immunoreactive nerve fibers. These fibers formed a plexus with numerous axonal varicosities predominantly innervating beta cells (Fig. 1, Supplementary Fig. 2 and Supplementary Video 1). By contrast, although many nerve fibers were immunostained for vAChT in the exocrine regions of the human pancreas, few if any fibers could be seen inside human islets (Fig. 1b) . Instead, many endocrine cells were strongly vAChT immunoreactive ( Fig. 1b and Supplementary Video 2) . Western blots confirmed the specificity of the vAChT staining and further showed that human islets express ChAT and choline transporter 1 (ChT1, Fig. 1d ). Because our experiments were conducted with isolated islets in which severed nerve fibers had degenerated after ≥ 2 d in culture 15, 16 , we were able to rule out the contribution of neuronal elements to the western blots and to the physiological experiments described below. Furthermore, we consistently found vAChT, ChAT and ChT1 mRNA expression in human islets that was comparable to or higher than that in the brain (Fig. 1e-g ). vAChT mRNA levels correlated with ChAT mRNA levels, as expected for gene products that share a common gene locus and regulatory elements for gene transcription 17 (Fig. 1h) . We thus conclude that human islet cells express the defining components of the cholinergic phenotype.
To localize the expression of vAChT to particular cell types within the human islet, we performed multiple immunostaining on human pancreatic sections (Fig. 2) . We found that most (~80%) vAChTlabeled cells were immunoreactive for glucagon (Fig. 2b) . Few vAChT cells expressed somatostatin or insulin (Fig. 2a,b) . More than 60% of glucagon-labeled alpha cells were strongly immunoreactive for vAChT (Fig. 2a) . Most alpha cells (>90%) were also immunoreactive Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming beta cell function in humans for ChAT (Fig. 2) . Within the alpha cell, vAChT staining did not overlap with glucagon staining and appeared confined to distinct compartments (Fig. 2c) . We examined the colocalization of vAChT and glucagon immunofluorescence 18 and found a Pearson's correlation coefficient significantly smaller than that of C peptide and insulin colocalization and closer to that of the clearly segregated nuclear DAPI and glucagon staining (Fig. 2d) . These findings concur with studies showing that in neuroendocrine cells, vAChT localizes preferentially to synaptic-like microvesicles and is excluded from hormone granules 19, 20 . Furthermore, human alpha cells have been reported to possess secretory vesicles of different sizes 21 . To determine whether acetylcholine and glucagon are stored in different secretory granules, however, would require electron microscopy studies.
Our immunohistochemical results suggested that in human alpha cells acetylcholine is packaged in secretory vesicles for exocytotic release. We therefore examined human islets for acetylcholine secretion using cellular biosensors, namely Chinese hamster ovary (CHO) cells expressing the muscarinic receptor M3 (Fig. 3) . We monitored acetylcholine secretion from human islets in real time by recording [Ca 2+ ] i responses from biosensors loaded with the [Ca 2+ ] i indicator Fura-2 and placed in apposition to isolated human islets (Fig. 3a) . The biosensors showed large responses to KCl-mediated depolarization (25 mM) of human islets (Fig. 3d) , indicating that acetylcholine release was induced from excitable islet cells and ruling out a contribution from exocrine tissue. Stimulation with kainate (100 µM) or lowering the glucose concentration from 16 mM to 3 mM, which are both alpha cell-specific stimuli 16, 22, 23 (Supplementary Fig. 3 ), induced strong acetylcholine release, as measured by large [Ca 2+ ] i responses in the biosensors (Fig. 3c,d ). By contrast, increases in the glucose concentration from 3 mM to 16 mM did not elicit acetylcholine secretion (Fig. 3c,d ). Biosensor responses could be blocked by the muscarinic antagonist atropine (5 µM), and none of the stimuli used, including KCl depolarization, induced responses in biosensors in the absence of human islets (Fig. 3b) . This confirmed that the [Ca 2+ ] i responses were elicited by acetylcholine released from islet cells. We obtained similar results using an enzymatic assay to detect acetylcholine release (Fig. 3e) . Because acetylcholine was released in response to treatments known to specifically stimulate alpha cells and not in response to increased glucose concentration, which stimulates beta and delta cells, we conclude that human alpha cells secrete acetylcholine.
We further used the biosensor assay to detect acetylcholine release from mouse islets. For these experiments, we cultured mouse islets for 4 d after isolation to eliminate neural elements, the same time as for human islets. Acetylcholine secretion could not be recorded from mouse islets stimulated with 25 mM KCl or 100 µM kainate (0 out of 26 mouse islets responded versus 17 out of 75 human islets; P = 0.0052, Fisher's exact test), consistent with the lack of vAChT immunostaining in mouse endocrine cells (Fig. 1a) .
What is the role of alpha cell-derived acetylcholine for islet function? Studies have shown that exposure to cholinergic agonists sensitizes beta cells to subsequent stimuli, increasing insulin secretion 1, 24 . Given that in human islets most beta cells are closely associated with alpha cells 25 , we hypothesized that alpha cells release acetylcholine to prime neighboring beta cells. To test this hypothesis, we first examined whether cholinergic agonists induce insulin responses in human beta cells. At low glucose concentration (3 mM), acetylcholine and the muscarinic agonist oxotremorine elicited concentration-dependent insulin release from isolated human islets, indicating that activation of muscarinic receptors can induce insulin secretion at basal glucose concentrations (Fig. 4a,b) .
To infer the role of acetylcholine as a paracrine signal we manipulated endogenous levels of acetylcholine. Applying the acetylcholinesterase inhibitor physostigmine (30 µM) at 3 mM glucose increased insulin secretion in isolated islets cultured for 4 d (Fig. 4c) . These insulin responses to physostigmine were strongly inhibited by vesamicol, a selective inhibitor of vAChT that blocks acetylcholine transport into vesicles and depletes cells of releasable acetylcholine (Fig. 4d) . We also found that physostigmine-induced increases in insulin secretion were partially inhibited by the M3 antagonist J-104129 (Fig. 4e) . This antagonist by itself reduced insulin secretion at 3 mM glucose, and this effect was negligible at 11 mM glucose (data not shown). Physostigmine-induced increases in insulin secretion were reduced at 11 mM glucose (Fig. 4f) . These experiments indicate that acetylcholine is endogenously released at low glucose concentrations to stimulate insulin secretion and that acetylcholine secretion requires vesicular mechanisms. These results are consistent with our immunohistochemical results showing the presence of vAChT in alpha cells. for ACh biosensor signals (∆340/380) in response to stimulation of islets with KCl (25 mM) depolarization (n = 8 experiments), kainate (100 µM, n = 11), increases in glucose concentration (from 3 mM to 16 mM, 3G-16G) or decreases in glucose concentration (from 16 mM to 3 mM, 16G-3G, n = 4). Biosensor responses were blocked by atropine (5 µM). (e) ACh release in response to increasing the glucose concentration from 3 mM to 11 mM (3G-11G), lowering the glucose concentration from 11 mM to 3 mM (11G-3G) or to depolarization with KCl (25 mM), as determined with a fluorescent enzymatic assay (see Online Methods; n = 6 islet preparations; ANOVA followed by multiple comparison, *P < 0.05). Data represent means ± s.e.m.
In vivo, the secretion of insulin and glucagon fluctuates constantly with periods of approximately 10 min 26, 27 . We hypothesized that these fluctuations allow alpha cells to increase acetylcholine secretion and influence beta cells. We reproduced these hormonal fluctuations in vitro by subjecting isolated human islets to an experimental protocol in which we stimulated beta cells and alpha cells intermittently while modulating cholinergic signaling (Fig. 4g,h and Supplementary Fig. 3 ). When acetylcholine degradation was inhibited with physostigmine (30 µM), insulin release increased during repeated exposure to high glucose (11 mM) (Fig. 4g,h) . Blocking muscarinic receptors with the general antagonist atropine (10 µM) produced variable results, most likely because multiple receptors on different cells were activated (data not shown). By contrast, adding the M3 receptor-specific antagonist J-104129 (50 nM) consistently reduced insulin responses (Fig. 4g,h) . These results show that endogenously released acetylcholine contributed to the enhanced beta cell response by activating M3 receptors. Thus, in the absence of any influence from the autonomic nervous system, endogenously released acetylcholine in human islets is able to sensitize the beta cell to subsequent increases in glucose concentration.
On the basis of our results, we propose that acetylcholine is a paracrine signal secreted by alpha cells in human islets. Our findings showing that alpha cells express vAChT and that alpha-specific stimuli induce acetylcholine secretion indicate that acetylcholine is stored in alpha cells for exocytotic release. In our model, alpha cells release acetylcholine when activated by lowering glucose concentration to prime the beta cell response to a subsequent increase in glucose concentration. Although additional paracrine effects of acetylcholine on other cells within the human islet (for example, delta cells) remain to be investigated, our results suggest that acetylcholine serves as a feedforward signal to keep the beta cell responsive to future challenges, thus limiting plasma glucose fluctuations. Moreover, the intracellular signaling pathways activated by acetylcholine may promote long-term survival of beta cells 28 , thus further suggesting that alpha cell-derived acetylcholine may act as a trophic factor. This paracrine interaction is only possible because of the unique cytoarchitecture of the human islet, where most beta cells are closely associated with alpha cells 25, 29, 30 . With beta cells comprising 64% and alpha cells most of the remaining volume in the human islet 31 , there is a high probability for a beta cell to be close to an alpha cell. Indeed, most beta cells (70-80%) face alpha cells 25, 30 and maintain a strong association even after dispersion of the islet 30 . This cellular arrangement is compatible with the notion that paracrine interactions occur via the interstitial space between endocrine cells, although the vascular route may also be used 32 . Thus, in human islets, alpha cells seem optimally placed to influence beta cells.
Although we cannot rule out a contribution of parasympathetic nervous input, our results suggest that cholinergic innervation of human islets may be sparse. This is consistent with studies showing that the influence of neural input on insulin secretion occurring before the actual absorption of nutrients (cephalic phase) has a relatively minor role in humans 33, 34 . Along these lines, vagotomized patients have normal postprandial serum insulin levels 35 , and individuals with type 1 diabetes who have undergone pancreas transplantation (and thus have denervated islets) remain euglycemic without therapy [36] [37] [38] . Furthermore, it is possible that the reported parasympathetic influence on islet function in human beings may be mediated by peptidergic axons 12 . The human islet may thus be self reliant in terms of cholinergic input. That acetylcholine is a paracrine signal, and not only a neural signal as in rodents, further implies that cholinergic signaling in human islets is activated under circumstances that cannot be modeled with rodent studies, highlighting the importance of species divergence in the pancreatic islet. Because cholinergic signaling pathways have been proposed as intervention points to promote beta cell function and survival 5 , our study has major implications for therapies in diabetes mellitus.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. Responses are expressed as percentage of the respective insulin response of control islets (100%, gray dashed line; n = 4 preparations for J-104129 treatment; n = 5 preparations for physostigmine treatment). One-sample t tests were used to compare the actual mean to a theoretical mean of 100% (control; *P < 0.05). Data represent means ± s.e.m.
